Evidence map›Paper›PMID 35855557›Full record

Trial reportClinical cardiology2022

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.

Benjamin L Freedman, David D Berg, Benjamin M Scirica, Erin A Bohula, Erica L Goodrich, Marc S Sabatine, David A Morrow, Marc P Bonaca

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.Journal of the American College of Cardiology · 2023 · on this map
    Article
  7. Article
  8. Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies.Journal of the Society for Cardiovascular Angiography & Interventions
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Benjamin L FreedmanDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0002-8533-0126
David D BergTIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0002-0366-5492
Benjamin M SciricaTIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Erin A BohulaTIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Erica L GoodrichTIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0002-8541-264X
Marc S SabatineTIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
David A MorrowTIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Marc P BonacaCPC Clinical Research, University of Colorado School of Medicine, Aurora, Colorado, USA.
Brigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USUniversity of Colorado Denver · US

Funding

American Heart Association Student Scholarship in Cardiovascular DiseaseHarvard Catalyst KL2/CMeRIT (NIH/NCATS UL 1TR002541)
6 · The paper itself

Abstract

backgroundHeart failure (HF) is a growing public health problem and ischemic heart disease is an important risk factor. Understanding the epidemiology of HF in patients with atherosclerosis may help identify subgroups at greater risk who have the potential to derive greater benefit from preventive strategies. METHODS AND

resultsThe TRA 2°P-TIMI 50 trial randomized 26,449 patients with stable atherosclerosis to the antiplatelet agent vorapaxar versus placebo. Hospitalization for HF (HHF) endpoints were adjudicated from serious adverse events by blinded structured review using established definitions. HHF incidence was estimated using Kaplan-Meier analysis. Independent predictors of HHF risk were identified using multivariable logistic regression. The effect of vorapaxar on HHF risk was explored using Cox regression. The estimated incidence of HHF at 3 years was 1.6%. Independent predictors of HHF included prior HF (adjusted odds ratio [adj-OR]: 8.31; 95% confidence interval [CI]: 6.56-10.54), age (adj-OR [per 10 years]: 1.67; 95% CI: 1.47-1.89), type 2 diabetes mellitus (T2DM; adj-OR: 2.55; 95% CI: 2.01-3.24), polyvascular disease (two-territory disease, adj-OR: 1.89; 95% CI: 1.46-2.44; three-territory disease, adj-OR: 2.68; 95% CI: 1.94-3.70), chronic kidney disease (CKD; adj-OR: 1.65; 95% CI: 1.30-2.11), body mass index (BMI; adj-OR [per 5 kg/m

conclusionsIn patients with stable atherosclerosis, prior HF, age, T2DM, polyvascular disease, CKD, BMI, prior MI, and hypertension are important predictors of HHF risk.

Indexed as

AtherosclerosisDiabetes Mellitus, Type 2Heart FailureHypertensionMyocardial InfarctionRenal Insufficiency, ChronicChildChild, PreschoolHospitalizationHumansRisk FactorsTreatment Outcomediabetesheart failurepolyvascular diseaserisk factorsstable atherosclerosisTIMI risk score for secondary preventionvorapaxar

Identifiers

PMID35855557
PMCPMC9346972
OpenAlexW4286215609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.